The Oral Typhoid Vaccine Market is witnessing steady expansion as rising typhoid cases and greater vaccination awareness encourage investment in preventive healthcare. The market is projected to increase from USD 900 million in 2025 to USD 2 billion by 2035, with a CAGR of 7.8%.

Manufacturers are focusing on technologies that improve vaccine formulation, stability, and delivery. Oral administration provides a convenient alternative to injectable vaccination, while research into more stable products could help simplify storage and distribution in developing healthcare markets.

The market covers live attenuated, inactivated, and conjugate vaccines. Children represent an important target population, while adults and elderly individuals also require protection, particularly in areas with high disease exposure or for people traveling to endemic regions.

Asia-Pacific leads the regional outlook due to high typhoid prevalence and extensive vaccination initiatives. Europe and North America have established healthcare systems and vaccination awareness, whereas South America and MEA offer additional opportunities as healthcare infrastructure and public-health programs improve.

The future market could be shaped by single-dose vaccines, combination products, improved temperature stability, and wider community-based vaccination programs. Digital health tools and data analytics may also help governments identify underserved populations and allocate vaccination resources more effectively.